Levofloxacin Hydrochloride for Injection

This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death. This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci.

The main ingredient of this product is levofloxacin hydrochloride, and its chemical name is (S)(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-[1,4]benzoxazine-6-carboxylic acid hydrochloride monohydrate

1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

Intravenous drip. Dissolve with an appropriate amount of sterile water for injection before use, and then dilute with 100mL of 5% glucose injection or sodium chloride injection twice for intravenous drip. Adults take 0.4g per day, divided into 2 intravenous drips. For patients with severe infections or pathogens with poor sensitivity to this product (such as Pseudomonas aeruginosa), the daily dose can be increased to 0.6g, divided into 2 intravenous drips.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. Occasionally may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. 2. Manifestations of interstitial nephritis such as hematuria, fever, and rash. 3. Crystalluria, more common when used in high doses. 4. Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, increased blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

It is contraindicated for patients who are allergic to quinolones, pregnant women, lactating women and patients under 18 years of age.

The intravenous infusion time of this product shall not be less than 60 minutes for every 100mL. Since Escherichia coli is currently resistant to fluoroquinolones, urine culture specimens should be collected before administration, and the medication should be adjusted based on the bacterial drug sensitivity results. Crystalluria may occur when this product is used in large doses or when the urine pH value is above 7. To avoid the occurrence of crystalluria, it is advisable to drink more water and maintain a 24-hour urine output of more than 1200mL. For patients with impaired renal function, the dosage should be adjusted according to renal function. When using this product, excessive exposure to sunlight should be avoided. If photosensitivity reactions or other allergic symptoms occur, the drug should be discontinued. When liver function is impaired, if it is severe (cirrhosis ascites), drug clearance can be reduced and blood drug concentrations can increase. This is particularly evident in patients with both liver and kidney function impairment. All patients need to weigh the pros and cons before using it, and the dosage should be adjusted. Patients with existing central nervous system diseases, such as epilepsy and a history of epilepsy, should avoid using it. When indicated, the pros and cons should be carefully weighed before using it. There are occasional reports of achillesitis or achilles rupture after medication. If any of the above symptoms occur, the medication should be discontinued immediately until the symptoms disappear.

Keep away from light, tightly closed, in a cool place.

0.4g

Shanxi Weiqidaguangming Pharmaceutical Co., Ltd.

• Founded in:

  2008-04-30

• Address:

  Datong Economic and Technological Development Zone First Pharmaceutical Park

• Tax NO.:

  91140200674471538G

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view